To include your compound in the COVID-19 Resource Center, submit it here.

Exelixis, Ipsen planning cabozantinib submissions in HCC

Exelixis Inc. (NASDAQ:EXEL) and partner Ipsen Group (Euronext:IPN; Pink:IPSEY) plan to submit regulatory applications in 2018 for cabozantinib (XL184) as a second-line treatment of advanced hepatocellular carcinoma (HCC) after the drug met the primary

Read the full 349 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE